BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10225148)

  • 1. Urokinase plasminogen activator system in humans with stable coronary artery disease.
    Krasnikova TL; Parfyonova Y; Alekseeva IA; Arefieva TI; Mukhina SA; Dobrovolsky AB; Titaeva Y; Lyakishev AA; Resink TJ; Erne P; Tkachuk VA
    Clin Exp Pharmacol Physiol; 1999 Apr; 26(4):354-7. PubMed ID: 10225148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
    Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
    Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients.
    Chung HC; Rha SY; Park JO; Yoo NC; Kim JH; Roh JK; Min JS; Lee KS; Kim BS; Kim JJ
    Breast Cancer Res Treat; 1998 May; 49(1):41-50. PubMed ID: 9694610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
    Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
    Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the urokinase plasminogen activator system in patients with bacterial meningitis.
    Winkler F; Kastenbauer S; Koedel U; Pfister HW
    Neurology; 2002 Nov; 59(9):1350-5. PubMed ID: 12427882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase-type plasminogen activator system and human cationic antimicrobial protein 18 in serum and induced sputum of patients with chronic obstructive pulmonary disease.
    Jiang Y; Xiao W; Zhang Y; Xing Y
    Respirology; 2010 Aug; 15(6):939-46. PubMed ID: 20624254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Urokinase-type plasminogen activator and its inhibitor type 1 in the diagnosis of evolving complications in coronary heart disease].
    Pal'tseva EM; Rodina AV; Andreev DA; Popova ON; Gusev DE; Severin SE; Syrkin AL
    Klin Lab Diagn; 2010 Jun; (6):51-5. PubMed ID: 20734863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dynamic changes in plasma levels of urokinase type plasminogen activator and urokinase type plasminogen activator receptor in patients with systemic inflammatory response syndrome].
    Wu XL; Yu L; Long D; Yang JH; Zhang YC; Geng F
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2011 Aug; 23(8):478-81. PubMed ID: 21878172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
    Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
    J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood urokinase plasminogen activator system in chronic urticaria.
    Kasperska-Zajac A; Brzoza Z; Rogala B
    Arch Dermatol Res; 2007 Jan; 298(8):409-11. PubMed ID: 17102952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
    Friess H; Duarte R; Kleeff J; Fukuda A; Tang WH; Graber H; Schilling M; Zimmermann A; Korc M; Büchler MW
    Surgery; 1998 Jul; 124(1):79-86. PubMed ID: 9663255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis.
    Strauss BH; Lau HK; Bowman KA; Sparkes J; Chisholm RJ; Garvey MB; Fenkell LL; Natarajan MK; Singh I; Teitel JM
    Circulation; 1999 Oct; 100(15):1616-22. PubMed ID: 10517732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
    Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M;
    J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of urokinase-type plasminogen activator and its receptor in plasma of patients with cerebral infarction].
    Song SJ; Hu JB; Wang HX; Wen SQ; Ding MP; Huang JZ
    Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(18):1583-5. PubMed ID: 14642114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.